Decreased clot burden is associated with factor XIII Val34Leu polymorphism and better functional outcomes in acute ischemic stroke patients treated with intravenous thrombolysis.

<h4>Background</h4>Intravenous thrombolysis using recombinant tissue plasminogen activator remains the mainstay treatment of acute ischemic stroke (AIS), although endovascular treatment is becoming standard of care in case of large vessel occlusions (LVO). To quantify the thrombus burden...

Full description

Bibliographic Details
Main Authors:	István Szegedi, Rita Orbán-Kálmándi, Attila Nagy, Ferenc Sarkady, Nikolett Vasas, Máté Sik, Levente István Lánczi, Ervin Berényi, László Oláh, Alexandra Crișan, László Csiba, Zsuzsa Bagoly
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2021-01-01
Series:	PLoS ONE
Online Access:	https://doi.org/10.1371/journal.pone.0254253

Internet

https://doi.org/10.1371/journal.pone.0254253

Decreased clot burden is associated with factor XIII Val34Leu polymorphism and better functional outcomes in acute ischemic stroke patients treated with intravenous thrombolysis.

Internet

Similar Items